The goal of this proposal was to determine if microRNA’s (miR) are elevated in the plasma of individuals affected by the inherited peripheral neuropathy Charcot-Marie-Tooth Disease, type 1A (CMT1A)
A new test may spur advances in drug discovery for a rare and debilitating neurological disorder. Charcot-Marie-Tooth disease, a rare inherited neurological disorder, affects more than 2.8 million people around the globe.
CMT is equally common among all ages, genders, and races and is one of the most common heritable neurological impairments. The symptoms present as neuropathy, foot drop, poor balance, difficulty with dexterity, or abnormal sensation – just to name a few.
Peripheral nerve myelination is adversely affected in the most common form of the hereditary peripheral neuropathy called Charcot-Marie-Tooth Disease. This form, classified as CMT1A, is caused by a 1.4 Mb duplication on chromosome 17, which includes the abundantly expressed Schwann cell myelin gene, Peripheral Myelin Protein 22 (PMP22).
Researchers at the University of Wisconsin–Madison have found a switch that redirects helper cells in the peripheral nervous system into “repair” mode, a form that restores damaged axons. Axons are long fibers on neurons that …
Every day, Waisman Center researcher John Svaren deals with nerves – peripheral nerves, that is. Peripheral nerves connect the brain and spinal cord to our limbs and organs, serving as vital communication relays that allow …
John Svaren, PhD’s paper “Genome editing-enabled HTS assays expand drug target pathways for Charcot-Marie-Tooth disease,” examines how the use of genome editing places his research one step closer to a potential cure for Charcot-Marie-Tooth disease.
Researchers funded by the National Institutes of Health have discovered how a defect in a single master gene disrupts the process by which several genes interact to create myelin, a fatty coating that covers nerve cells and increases the speed and reliability of their electrical signals.